Pace of Life Syndrome is directly linked to the already published blog posts about Borderline Personality Disorder (BPD) and allostatic load. This article explores the psycho-epigenetics of Pace of Life Syndrome in depth — examining how early adversity and life events encode themselves biologically through epigenetic mechanisms, how these mechanisms shape identity and personality across the lifespan, and how death anxiety intersects with and amplifies this framework to produce measurable consequences for psychological and physical health.
Advertisements
Epigenetics is the study of how outside influences can change the way our genes work without changing our DNA itself. It looks at how things in our environment—like what we eat, how much stress we feel, our daily habits, and our life experiences—can turn genes on or off. These changes can affect how our cells work and how we develop, and they can sometimes be passed on to future generations. Among the most profound reorientations in contemporary psychological and biological science is the recognition that human identity, personality, and health outcomes are not fixed properties of genetic inheritance alone — they are dynamic, experience-dependent, and continuously rewritten by the events, environments, and relationships that constitute a human life.
The emerging field of psycho-epigenetics—the study of how our psychological experiences can cause lasting changes in how our genes are expressed, without changing the DNA sequence itself—now shows, at the level of our cells, how this process works (Cowell, 2019). When this framework is combined with the evolutionary model called the Pace-of-Life Syndrome (PoLS)—which suggests that organisms adjust their whole biological and behavioural profile in response to early-life conditions of adversity and unpredictability—it offers a clear and clinically important explanation of how lived experience shapes who we become(Réale et al., 2018), in our very bodies …
Subscribe to continue reading
Read more of this exclusive content when you subscribe today.
Epel, E.S., Blackburn, E.H., Lin, J., Dhabhar, F.S., Adler, N.E., Morrow, J.D. and Cawthon, R.M. (2004) ‘Accelerated telomere shortening in response to life stress’, Proceedings of the National Academy of Sciences, 101(49). Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC534658/ (Accessed: 25 July 2026).
Glick, D. et al. (2025) ‘From trauma to resilience: psychological and epigenetic adaptations in the third generation of Holocaust survivors’, Scientific Reports, 15. Available at: https://www.nature.com/articles/s41598-025-12085-5 (Accessed: 25 July 2026).
Kaminsky, Z. et al. (2024) ‘On the role of epigenetic modifications of HPA axis in posttraumatic stress disorder and resilience’, Journal of Neurophysiology, 131(5). Available at: https://journals.physiology.org/doi/full/10.1152/jn.00345.2024 (Accessed: 25 July 2026).
Lindqvist, D., Epel, E.S., Mellon, S.H., Penninx, B.W., Révész, D., Verhoeven, J.E., Reus, V.I., Lin, J., Mahan, L., Hough, C.M., Rosser, R., Wolkowitz, O.M. (2015) ‘Childhood Adversities Are Associated with Shorter Telomere Length at Adult Age both in Individuals with an Anxiety Disorder and Controls’, PLOS ONE. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC2876034/ (Accessed: 25 July 2026).
Otto, B., Kokkelink, L. and Brüne, M. (2021) ‘Borderline Personality Disorder in a “Life History Theory” Perspective: Evidence for a Fast “Pace-of-Life-Syndrome”‘, Frontiers in Psychology, 12, 715153. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350476/ (Accessed: 25 July 2026).
Perroud, N. et al. (2018) ‘Epigenetics in Personality Disorders: Today’s Insights’, Frontiers in Psychiatry. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC6252387/ (Accessed: 25 July 2026).
Qiu, J. and Xu, X. (2025) ‘On the effectiveness of Buddhist view of life and death in regulating mortality salience’, Frontiers in Psychology, 15, 1523125. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11751067/ (Accessed: 25 July 2026).
Réale, D., Garant, D., Humphries, M.M., Bergeron, P., Careau, V. and Montiglio, P.O. (2010) ‘Personality and the emergence of the pace-of-life syndrome concept at the population level’, Philosophical Transactions of the Royal Society B: Biological Sciences, 365(1560), pp. 4051–4063. Available at: https://royalsocietypublishing.org/doi/abs/10.1098/rstb.2010.0208 (Accessed: 25 July 2026).
Réale, D., Montiglio, P.O., Dingemanse, N.J. and Moiron, M. (2018) ‘Pace-of-life syndromes: a framework for the adaptive integration of behaviour, physiology and life history’, Behavioral Ecology and Sociobiology, 72, 116. Available at: https://link.springer.com/article/10.1007/s00265-018-2473-y (Accessed: 25 July 2026).
Trigeminal Neuralgia (TN) is a rare but devastating neuropathic condition characterised by sudden, electric shock-like episodes of excruciating facial pain distributed along the branches of the trigeminal nerve — the fifth cranial nerve, responsible for sensation across the face. The attacks are frequently triggered by the most mundane of stimuli: brushing teeth, speaking, eating, or even the touch of a gentle breeze. The severity of pain has long been described as among the most intense that human physiology is capable of producing, earning TN its well-known and historically significant designation as the “suicide disease” (Neto et al., 2025).
While this label has been challenged in recent years as medical and surgical treatments have advanced, its existence is not without clinical basis. The psychological burden imposed by long-term TN is substantial, multidimensional, and — critically — profoundly underestimated within mainstream healthcare. This article examines how trigeminal neuralgia influences psychological changes over time, exploring the bidirectional relationship between chronic pain and mental health, the specific psychiatric conditions associated with TN, the risk of suicidality, the disruption to social and occupational functioning, and what the evidence recommends for integrated clinical management.
Advertisements
A Bidirectional Relationship: Pain and Mental Health
The relationship between trigeminal neuralgia and psychological disorders is not unidirectional. Traditionally, the assumption has been that the pain of TN causes secondary mood changes such as depression and anxiety — a logical and intuitive proposition. However, emerging research using Mendelian randomisation analysis — a methodology that applies genetic markers to establish causal direction — has demonstrated that the relationship is in fact bidirectional: not only does TN precipitate psychiatric illness, but pre-existing mental health conditions including depression, anxiety, and insomnia also significantly increase the risk of developing TN in the first instance (Wang et al., 2025).
A landmark 2025 study published in The Journal of Headache and Pain found that people with depression were more than twice as likely to develop TN, while insomnia and anxiety also significantly elevated TN onset risk. Conversely, carrying a diagnosis of TN increased the risk of developing anxiety by 43%, depression by 30%, and insomnia by nearly 40% (TNA, 2025). Furthermore, the study confirmed that longer disease duration and broader trigeminal nerve involvement were independently associated with increased severity of depressive, anxiety, and insomnia symptoms — underscoring a dose-response relationship between the chronicity of TN and the depth of its psychological toll (Wang et al., 2025).
Depression: The Most Prevalent Psychological Consequence
Depression is the most consistently documented psychological comorbidity in TN populations and one of the most clinically consequential. The mechanism is well-evidenced: chronic, unrelenting pain of the intensity characteristic of TN depletes neurochemical resources, disrupts sleep architecture, undermines the capacity for daily functioning, and progressively narrows the individual’s world — all known aetiological contributors to major depressive disorder (Wu et al., 2019). The unpredictability of TN attacks — which can occur without warning at any moment during waking hours — generates a state of sustained psychological vigilance that, over time, mirrors the cognitive and physiological features of a depressive episode.
A systematic review published in Neurosurgery Reviews in 2025 — the first of its kind to comprehensively examine the psychological burden of TN — confirmed that TN patients carry significantly elevated rates of depressive disorders across multiple validated assessment tools, including the PHQ-9, Hamilton Depression Rating Scale, and Hospital Anxiety and Depression Scale. Critically, the review also found that surgical treatments, particularly microvascular decompression (MVD), effectively alleviated both pain and depressive symptoms, while multidisciplinary approaches combining psychological support with neurorehabilitation yielded the best overall outcomes — a finding with direct implications for how NHS services structure TN care pathways (Martinelli et al., 2025).
Anxiety, Anticipatory Fear, and Catastrophising
Anxiety in TN takes a form that is, in many respects, distinct from generalised anxiety disorder as it presents in the broader population. The central driver is anticipatory fear — the perpetual, hypervigilant dread of the next attack. Because TN pain is triggered by ordinary activities that cannot be permanently avoided — talking, eating, drinking, facial exposure to air — affected individuals frequently develop avoidance behaviours that progressively restrict their lives. They stop eating in public. They cease speaking unnecessarily. They avoid wind, cold, and touch with an intensity that begins to resemble phobic avoidance (Wu et al., 2019).
Research comparing patients with TN against those with persistent idiopathic facial pain found that anxiety symptoms were significantly more elevated in the TN group, and that for individuals reporting prior trauma exposure, PTSD symptoms were also significantly greater among TN patients than comparison groups (ScienceDirect, 2025). The phenomenon of pain catastrophising — a cognitive pattern in which individuals magnify the threat value of pain, ruminate on its impact, and feel helpless in the face of it — is documented at elevated rates in TN and has been shown to independently worsen both pain perception and psychological outcomes over time (Frontiers in Neurology, 2025).
PTSD, Trauma, and the Neurological Siege
The conceptualisation of TN-related suffering within a trauma framework is gaining increasing traction in the clinical literature, and it is not difficult to understand why. The lived experience of TN — sudden, violent, entirely unpredictable episodes of pain that resist personal control and occur in the context of innocuous daily activities — shares structural features with the traumatic experiences that give rise to post-traumatic stress disorder. The nervous system learns to associate ordinary environmental stimuli with overwhelming threat, generating the hyperarousal, intrusive re-experiencing, and avoidance behaviours that characterise PTSD (Neto et al., 2025).
Emerging evidence confirms that PTSD symptoms are measurably elevated in TN populations, particularly in those with longer disease duration, greater pain intensity, and inadequate treatment response. The systematic review by Martinelli et al. noted that sleep disorders — which are independently associated with the development and maintenance of PTSD — were among the most prevalent and underaddressed comorbidities in TN patients, creating a reinforcing cycle of neurological and psychological distress that becomes progressively more difficult to interrupt without targeted intervention (Martinelli et al., 2025).
Suicidality: An Urgent and Under-Addressed Clinical Concern
The designation of TN as the “suicide disease” demands honest and careful clinical scrutiny. A 2025 study conducted by researchers from Harvard Medical School and Massachusetts General Hospital — the largest study to date examining suicidality in TN — recruited 229 adults with TN and related conditions between December 2023 and January 2024. Their findings were sobering: suicidal ideation was found at clinically significant rates within the sample, and was strongly associated with high pain intensity, elevated anxiety, and severe depression (Fishbein, Bakhshaie and Greenberg, 2025). The authors concluded that suicidality is an urgent yet substantially under-addressed concern among adults with TN, and that its association with pain intensity places comprehensive psychological screening at the centre of responsible clinical management.
Research examining psychological status in TN patients before and after surgical intervention has further identified that the risk of suicidal ideation is significantly higher in patients with atypical TN (TN2) than in those with classical TN (TN1), requiring more intensive psychological monitoring in this subgroup — and supporting the argument that indications for surgical treatment should be established with urgency in patients at elevated psychological risk (ScienceDirect, 2021). While the “suicide disease” label may now be contextually outdated given advances in surgical and pharmacological treatment, it retains clinical utility as a reminder of the severity of psychological risk that chronic, inadequately managed TN produces (Neto et al., 2025).
Social Isolation, Identity, and Occupational Disruption
Beyond the domain of discrete psychiatric diagnoses, TN exerts a pervasive and devastating influence on social functioning, personal identity, and occupational engagement. The avoidance behaviours generated by anticipatory fear — the withdrawal from eating, speaking, and social interaction — progressively erode the structures around which personal identity is built. Work becomes impossible, or severely constrained, for many individuals during active disease phases. Social relationships deteriorate under the weight of unexplained withdrawal and communicative limitation. For those who depend on speech professionally — teachers, therapists, lawyers, performers — the occupational consequences can be total and permanent (TNA, 2025).
The psychological literature consistently identifies social isolation as both a consequence and an amplifier of chronic pain, generating a self-reinforcing cycle in which pain produces withdrawal, withdrawal reduces protective social buffering, and the absence of social support intensifies the subjective experience and psychological weight of pain. In TN, where the very act of social communication — speaking — can trigger an attack, this cycle is particularly vicious and particularly difficult to interrupt without targeted psychosocial intervention alongside physical pain management (Frontiers in Neurology, 2025).
Treatment Implications: The Case for Multidisciplinary Care
The weight of evidence reviewed here makes a compelling and unambiguous case for the integration of psychological support into the standard clinical management of trigeminal neuralgia. Pharmacological and surgical interventions — carbamazepine and oxcarbazepine as first-line medications, microvascular decompression as the preferred surgical option for suitable candidates — address the neurological substrate of TN pain with variable success, but do not in themselves address the psychological sequelae that accumulate across the duration of the illness (Martinelli et al., 2025).
The systematic review by Martinelli et al. explicitly concluded that standardising psychological assessment and treatment methodologies is crucial for optimising TN management outcomes — and that multidisciplinary approaches combining psychological support with neurorehabilitation consistently yield superior results to purely biomedical approaches alone. The Trigeminal Neuralgia Association UK has similarly called for psychological therapy, pain counselling, and sleep support to be embedded as standard within TN care pathways — not optional additions, but structural components of responsible clinical provision (TNA, 2025).
Conclusion
Trigeminal neuralgia is not merely a condition of the face. It is a condition of the whole person — neurological in origin, but psychological in consequence, social in impact, and existential in the challenges it poses to identity, connection, and the basic quality of human experience. The long-term psychological changes it produces — depression, anxiety, anticipatory fear, PTSD-like trauma responses, suicidal ideation, social withdrawal, and occupational collapse — are not incidental features of living with chronic pain. They are clinical realities that demand clinical responses: structured, evidence-based, and delivered alongside rather than after physical pain management. Recognising TN as the biopsychosocial emergency it truly is remains one of the most important steps the clinical and research communities can take toward meaningfully improving outcomes for those who live with this condition.
If you or someone you know is living with chronic pain and experiencing thoughts of suicide or self-harm, please contact the Samaritans on 116 123 (free, 24/7 in the UK) or speak to your GP or local NHS mental health service as soon as possible. If you are seeking help from outside the UK, call your local support service.
Martinelli, R., Vannuccini, S., Burattini, B., D’Alessandris, Q.G., D’Ercole, M., Izzo, A., Chieffo, D.P.R., Doglietto, F. and Montano, N. (2025) ‘Psychological assessment in patients affected by trigeminal neuralgia: a systematic review’, Neurosurgery Reviews, 48(1), 414. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12069416/ (Accessed: 10 June 2026).
Neto, R., Fonseca Silva, B., Remelhe, M. and Araujo, R. (2025) ‘Trigeminal Neuralgia — rethinking the “suicide disease” label’, European Psychiatry. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12438733/ (Accessed: 10 June 2026).
Wang, J., Li, M., Zhang, Z., Duan, Y., Zhang, Z., Liu, H. et al. (2025) ‘Association between mental disorders and trigeminal neuralgia: a cohort study and Mendelian randomization analysis’, The Journal of Headache and Pain, 26, 74. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC11992777/ (Accessed: 10 June 2026).
Among the many sobering realities associated with Borderline Personality Disorder (BPD), perhaps none demands more urgent clinical and public attention than its profound impact on life expectancy. A claim now circulating widely in mental health discourse — that BPD can shorten a person’s life by up to 20 years — is not a figure born of speculation. It is grounded in a growing body of peer-reviewed longitudinal research that collectively paints a troubling picture of premature mortality risk in this population. Yet the “20-year” headline, while broadly accurate, is more nuanced than it first appears. The evidence points to a range of outcomes shaped by comorbidities, socioeconomic factors, access to care, and biological mechanisms that science is only beginning to fully understand. This article examines that evidence in detail, interrogating where the figure comes from, what drives it, and what can be done to narrow the gap.
Advertisements
Where Does the “20-Year” Figure Come From?
The most frequently cited estimate is that individuals with BPD face a reduction in life expectancy of approximately 10 to 20 years compared to the general population (Euler et al., 2025). Other studies extend this further: longitudinal research has estimated that people with personality disturbances more broadly — with BPD representing the most clinically severe — face a reduction in life expectancy of between 13 and 27.5 years, owing to a substantially elevated all-cause mortality risk, particularly among younger individuals (Rincón Ferrari et al., 2024). This wide range reflects genuine variation in study design, sample characteristics, and follow-up periods — but across all estimates, the direction of the evidence is unambiguous: BPD is associated with markedly shortened lifespans.
The most methodologically rigorous evidence underpinning this claim comes from the McLean Study of Adult Development (MSAD), a prospective 24-year longitudinal investigation conducted at Harvard-affiliated McLean Hospital. Following 290 patients with BPD against 72 comparison patients with other personality disorders, the study found that after 24 years, 5.9% of BPD patients had died by suicide, compared with 1.4% of comparison patients. More strikingly, a further 14.0% of BPD patients died from other causes — nearly three times the 5.5% rate observed in the comparison group (Temes et al., 2019). The principal investigators concluded that premature mortality in BPD is comparable in scale to that observed in other serious mental illnesses, including schizophrenia and treatment-resistant mood disorders (Medscape, 2019).
Suicide: Real, Significant, But Not the Whole Story
Any honest discussion of BPD mortality must begin with suicide, which remains the most clinically visible and statistically documented contributor to early death in this population. Between 46% and 92% of individuals with BPD will attempt suicide at least once during their lifetime, and between 3% and 10% will die by suicide — a rate dramatically higher than both the general population and many other psychiatric diagnoses (Euler et al., 2025). Factors shown to predict completed suicide in BPD include prior suicidal behaviour, a greater number of psychiatric hospitalisations, and the presence of significant psychiatric comorbidities (Medscape, 2019).
However, a critical finding from the McLean MSAD and subsequent studies is that suicide alone does not account for the full extent of the mortality gap. In the McLean cohort, non-suicidal causes of death — including cardiovascular disease (n=11), substance-related complications (n=5), cancer (n=4), and accidents (n=4) — collectively exceeded suicide as a cause of premature death in BPD patients who did not achieve recovery (Temes et al., 2019). This finding has significant implications for how clinicians approach the condition: a singular focus on suicide prevention, while essential, is insufficient to address the full spectrum of life-threatening risk.
Physical Health: The Silent Driver of Early Death
The physical health burden carried by individuals with BPD is substantially underappreciated in mainstream clinical and public discourse. Research confirms that BPD independently elevates the risk of cardiovascular disease, hypertension, obesity, diabetes, arteriosclerosis, arthritis, gastrointestinal disorders, hepatic disease, and sexually transmitted infections (Rincón Ferrari et al., 2024). A dedicated echocardiographic study found that female BPD patients showed significantly increased epicardial adipose tissue — an established sensitive marker for cardiovascular disease risk — alongside reduced indices of cardiac function, compared to matched controls, suggesting that structural cardiac changes may begin early in the illness course (Euler et al., 2025).
The theoretical framework known as the “Pace-of-Life Syndrome” offers one explanatory model for why physical deterioration occurs so pervasively in BPD. Rooted in evolutionary biology, this framework argues that the chronic stress, early adversity, and emotional hyperreactivity characteristic of BPD produce a state of elevated allostatic load — the cumulative physiological wear caused by chronic psychological stress — that accelerates biological ageing and systemic organ damage over time (Otto, Kokkelink and Brüne, 2021). In clinical settings, BPD is associated with an 8.3-fold higher all-cause mortality compared to the general population — a figure that situates it firmly in the category of serious public health concern (Otto, Kokkelink and Brüne, 2021).
Comorbidities and the Compounding Effect
BPD rarely exists in isolation, and the life expectancy implications of its comorbidities are considerable. The vast majority of individuals diagnosed with BPD also experience at least one mood disorder — most commonly major depressive disorder or bipolar disorder — alongside elevated rates of anxiety disorders, post-traumatic stress disorder, eating disorders, and attention-deficit hyperactivity disorder (MH Stats, 2026). Substance Use Disorders (SUD) are present in approximately 60% of clinical BPD samples and constitute one of the strongest independent predictors of non-suicidal premature death, contributing directly to cardiovascular complications, accidental overdose, and immune system compromise over time (Grouport Therapy, 2023).
The temporal dimension of BPD across the lifespan adds further complexity. Research shows that while core BPD symptoms — including affective dysregulation, impulsivity, and suicidality — tend to diminish in intensity with age, maladaptive interpersonal functioning and functional impairment often persist and evolve in presentation, meaning that risk does not simply disappear as patients grow older (Zanarini et al., 2019). The cumulative toll of decades of emotional dysregulation, poor health behaviours, medication side effects, and systemic neglect by healthcare services produces a form of accelerated biological ageing that is difficult to reverse in later life.
Stigma, Systemic Barriers, and the Access Gap
A crucial but frequently overlooked contributor to the mortality gap in BPD is the pervasive stigma attached to the diagnosis — both among the general public and within healthcare systems themselves. Individuals with BPD consistently report experiencing negative, dismissive, or even punitive treatment from health practitioners, which generates significant reluctance to seek medical care and sustain treatment engagement (Euler et al., 2025). This stigma compounds the already considerable barriers to accessing consistent, high-quality physical and mental healthcare — particularly in under-resourced healthcare systems where BPD-specific expertise is limited (MH Stats, 2026). A significant treatment delay exists between the onset of BPD symptoms, which often emerge in adolescence, and the point at which an individual first receives an accurate diagnosis and appropriate care (MH Stats, 2026).
Closing the Gap: What the Evidence Recommends
The mortality gap associated with BPD is not immutable. Effective interventions exist, and early deployment of these interventions measurably improves both quality of life and long-term survival outcomes. Dialectical Behaviour Therapy (DBT), the gold-standard treatment specifically developed for BPD, has demonstrated robust efficacy in reducing self-harm, suicidality, emotional dysregulation, and the impulsive health-damaging behaviours that drive early physical deterioration (Biology Insights, 2025). Researchers from McLean Hospital have called for treatment models that go beyond symptomatic management to actively address poor health behaviours, substance use, social isolation, and physical health monitoring — paralleling rehabilitation approaches used in schizophrenia care (Medscape, 2019).
Integrated care models that coordinate psychiatric treatment with primary and physical healthcare are strongly supported by current evidence (Biology Insights, 2025). The scientometric literature on BPD spanning twenty years of published research has also called for greater global investment in BPD-specific clinical trials, standardised treatment protocols, and anti-stigma initiatives at both clinical and policy levels (Liu et al., 2024).
Conclusion
The evidence that BPD can shorten life expectancy by up to 20 years — and in some studies considerably more — is neither a myth nor an exaggeration. It is a research-grounded reality that emerges consistently across longitudinal studies, biological investigations, and clinical reviews. Suicide, while a defining risk, is only one contributor within a broader constellation of physical illness, psychiatric comorbidity, substance use, systemic neglect, and chronic biological stress that collectively erodes the lifespans of those living with this diagnosis. What the science now makes clear is that BPD must be treated not merely as a mental health condition, but as a serious, life-limiting illness warranting the same level of coordinated, sustained, and adequately funded clinical attention that other life-shortening disorders receive.
If you or someone you know is living with BPD or experiencing thoughts of self-harm or suicide, please reach out for support. In the UK, contact NHS 111 (option 2), or the Samaritans on 116 123 (free, 24/7). In the US, call or text 988 (Suicide and Crisis Lifeline). Wherever you are, seek support if you don’t already have it.
Medscape (2019) ‘Early Death in BPD Patients Not Just Because of Suicide’, Medscape, 24 May. Available at: https://www.medscape.com/viewarticle/913222 (Accessed: 1 June 2026).
Otto, B., Kokkelink, L. and Brüne, M. (2021) ‘Borderline Personality Disorder in a “Life History Theory” Perspective: Evidence for a Fast “Pace-of-Life-Syndrome”‘, Frontiers in Psychology, 12, 715153. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350476/ (Accessed: 1 June 2026).
Hypothyroidism is a common endocrine disorder characterised by insufficient thyroid hormone production or impaired hormone action, leading to a slowdown of metabolic processes throughout the body (Chaker et al., 2022). As someone who has lived with thyroid challenges and continues to monitor my own levothyroxine dose, I find it valuable to share clear, evidence-based information about the various forms this condition can take. Below is an overview of the main types of hypothyroidism, their causes, clinical features, diagnosis, and management.
Advertisements
1. Primary Hypothyroidism
Primary hypothyroidism is the most frequent form, accounting for over 95% of cases in iodine-sufficient regions (Jonklaas et al., 2014). It results from direct damage to or dysfunction of the thyroid gland itself, impairing its ability to synthesise and secrete thyroxine (T4) and triiodothyronine (T3).
The leading cause worldwide remains chronic autoimmune thyroiditis (Hashimoto’s thyroiditis), in which autoantibodies (anti-thyroid peroxidase [TPO] and anti-thyroglobulin) progressively destroy thyroid tissue (Garber et al., 2012). Other important aetiologies include:
Iodine deficiency (still prevalent in parts of Africa, South Asia and some mountainous regions).
Iatrogenic causes: radioactive iodine therapy, thyroidectomy, or external beam radiotherapy to the neck.
Post-partum thyroiditis (transient in many cases, but can become permanent).
Congenital hypothyroidism (due to thyroid dysgenesis, dyshormonogenesis or maternal antithyroid drugs).
Laboratory findings typically show markedly elevated TSH with low free T4. Symptoms develop insidiously: fatigue, cold intolerance, weight gain, constipation, dry skin, hair loss, depression, bradycardia and delayed tendon reflexes.
Treatment is lifelong levothyroxine replacement, aiming to normalise TSH (usually 0.4–4.0 mIU/L, though individual targets vary) (Jonklaas et al., 2014). Regular monitoring every 6–12 months is recommended once stable.
2. Central (Secondary and Tertiary) Hypothyroidism
Central hypothyroidism arises from pituitary (secondary) or hypothalamic (tertiary) dysfunction, resulting in inadequate TSH secretion despite low circulating thyroid hormones. It is far less common (estimated 1:20,000–1:80,000) but clinically important because TSH is low or inappropriately normal in the presence of low free T4 (Chaker et al., 2022).
Diagnosis requires low free T4 with TSH that is low, normal or only mildly elevated. Free T3 may also be low. MRI of the pituitary is often indicated. Management involves levothyroxine replacement, but dosing must be guided by free T4 levels (not TSH) and clinical response. Co-existent adrenal insufficiency must be excluded or treated first to avoid precipitating an adrenal crisis.
3. Subclinical Hypothyroidism
Subclinical hypothyroidism is defined biochemically by elevated TSH with normal free T4 and free T3 concentrations. Prevalence increases with age, reaching 10–20% in people over 60 years. Most cases are mild (TSH 4.5–10 mIU/L) (Pearce et al., 2016).
The decision to treat remains controversial and is guided by:
TSH level (>10 mIU/L is more likely to benefit from treatment).
Presence of symptoms.
Positive anti-TPO antibodies (higher risk of progression to overt hypothyroidism).
Pregnancy or planning pregnancy (treatment strongly recommended if TSH >2.5–4.0 mIU/L depending on trimester) (Alexander et al., 2017).
Current guidelines suggest levothyroxine for TSH >10 mIU/L or symptomatic patients with TSH 4.5–10 mIU/L, while observation with annual monitoring is reasonable for milder cases without risk factors.
4. Transient and Drug-Induced Hypothyroidism
Several situations cause temporary thyroid failure:
Post-partum thyroiditis – biphasic (thyrotoxic then hypothyroid phase), resolves in 80–90% of cases.
Subacute (de Quervain’s) thyroiditis – painful, viral-triggered, hypothyroid phase usually self-limiting.
Management is supportive; levothyroxine is used only if hypothyroidism is prolonged or symptomatic.
5. Congenital Hypothyroidism
Congenital hypothyroidism affects 1 in 2,000–4,000 newborns and is usually due to thyroid dysgenesis (absent or ectopic gland) or dyshormonogenesis. Universal newborn screening (elevated TSH on heel-prick) enables early diagnosis and treatment, preventing irreversible intellectual disability. Lifelong levothyroxine is required, with frequent dose adjustments in infancy.
Clinical and Practical Considerations
Regardless of type, untreated hypothyroidism increases cardiovascular risk (dyslipidaemia, hypertension, heart failure), impairs quality of life and, in severe cases (myxoedema coma), becomes life-threatening. Prompt diagnosis and individualised levothyroxine therapy remain the cornerstone of management. Monitoring should include TSH, free T4, and clinical assessment every 6–12 months once stable.
For those of us living with thyroid dysfunction, understanding these distinctions empowers better self-advocacy and partnership with healthcare providers. Knowledge truly is a form of healing.
I see 2026 as a pivot: AI’s deeper weave, geopolitical fractures, mental health reckonings, and economic shifts. Drawing from expert forecasts, here are 24 predictions spanning technology, geopolitics, psychology, markets, business, lifestyle, law, and health. These aren’t speculation but synthesised insights, equipping us to navigate ahead.
Advertisements
1. Agentic AI Becomes Mainstream: Autonomous AI agents will handle complex workflows, significantly boosting productivity by 20-30% in various enterprises across different sectors (Forbes, 2025). While this remarkable advancement may lead to improved efficiency and innovation, it is important to note that this technological shift might also cause the loss of some jobs, raising concerns about workforce displacement and the need for upskilling in the evolving job market.
2. Quantum Computing Commercial Breakthroughs: Quantum sensors deliver value in navigation and medical imaging, with error-corrected systems emerging (The Quantum Insider, 2025).
3. AR/VR “iPhone Moment”: Spatial computing via affordable glasses integrates daily life, blending digital-physical seamlessly. These innovations promise to disrupt traditional methods of communication and consumption. We can expect an increasingly immersive experience, enabling users to navigate their surroundings with augmented insights and interact with digital content that feels all the more tangible and intuitive (The Innovation Mode, 2025).
4. AI Sovereignty Rises: Nations will prioritise domestic AI models for security, fragmenting global tech (Stanford HAI, 2025).
5. Multimodal AI Dominates: Models processing text, image, video, and audio advance research and creativity significantly. The continuous improvement and integration of these models are expected to inspire groundbreaking advancements in the upcoming years, ultimately changing the digital landscape (Microsoft Source, 2025).
7. Youth Mental Health Crisis Peaks: The impacts of technology on mental health are commanding significant attention, as the rise of AI companions emerges as a potential avenue for support and intervention. Experts will be increasingly concerned about the mental well-being of young people in the face of growing digital pressures and social media influences. (UNC News, 2026).
8. Russia Bolsters Alliances: Deeper ties with China, North Korea amid isolation (The Diplomat, 2025).
9. AI in Therapy Grows Cautiously: Tools aid access, ethical concerns slow adoption as therapists navigate the complexities of integrating artificial intelligence into traditional therapeutic practices, but all this will will be slowed down due to concerns about ethical standards and client privacy. (APA Monitor, 2026).
10. Burnout and “Quiet Quitting” Evolve: The workforce increasingly priorities personal boundaries amid rising remote work options, leading to an emphasis on holistic remote care and mental health strategies to support employee well-being and productivity. (Spring Health, 2025).
11. Multipolar World Solidifies: Geoeconomic fragmentation is on the rise, making it tougher for the US to keep its top spot (World Economic Forum, 2026).
12. Neurodiversity Focus Intensifies: Workplace accommodations standardise and enhance the working conditions for neurodiverse individuals, ensuring that their unique strengths and challenges are acknowledged and supported effectively (Grow Therapy, 2025).
13. Middle East Volatility Persists: Gaza – Lebanon risks spillover, no major resolution (Stimson Center, 2026).
14. Psychedelic Therapies Expand: Regulatory approvals for novel treatments for PTSD and depression, providing new hope for patients seeking alternative solutions to traditional therapeutic methods and medications. (UCLA Health, 2025).
15. Global Growth at 3.1%: The driving forces behind this notable figure are the economies of the US, Europe, and Asia, while advancements in artificial intelligence continue to fuel substantial gains across various sectors, contributing significantly to the economic landscape. (Bloomberg, 2026).
16. M&A in Crypto Surges: Record deals as regulation clarifies, driving significant investment and strategic partnerships within the industry. This surge can be attributed to the increasing clarity in regulatory frameworks that shape the crypto landscape. As major players, including traditional financial institutions and innovative startups, join forces, the potential for growth and innovation will skyrocket (Silicon Valley Bank, 2025).
18. Crypto Tokenisation Booms: As stablecoins continue to grow in popularity and usage, the integration of traditional assets with digital platforms is expected to revolutionise the way we perceive and conduct transactions (World Economic Forum, 2026).
19. AI-Driven Earnings Boost Stocks: The tech sectors are leading the charge in this new era of investment, showcasing significant growth potential amid increasing interest in artificial intelligence applications. This upward trajectory, however, is not without its challenges, as volatility stemming from policy changes can create a rollercoaster effect in market dynamics. As we look ahead, the interplay between tech advancements and policy frameworks will be crucial in determining the sustainability of these gains (Reuters, 2026).
20. GLP-1 Drugs Expand: As awareness about obesity-related health risks grows, the demand for GLP-1 medications will likely increase, prompting further research and development in this field. This may enhance patient outcomes, making them a crucial component of future therapeutic strategies aimed at combating the global obesity epidemic. (Advisory Board, 2026).
21. AI Regulation Accelerates: Global frameworks for ethics will be established, addressing crucial issues surrounding accountability and transparency. There will be increased safety measures implemented, ensuring human rights. This progress is anticipated as governments and organisations come together to create comprehensive policies that govern the use and development of AI systems. (Tech Policy Press, 2026).
23. Sustainability Lifestyles Rise: Eco-conscious choices, play, and sleep will be prioritised amid climate risks, highlighting the increasing awareness of individuals to adopt greener habits in their daily routines. This shift will become increasingly apparent in various aspects of life, such as diet, transportation, and leisure activities, all framed within the context of preserving our planet for future generations. (NY Times, 2025).
In conclusion, 2026 promises acceleration: AI’s transformative embrace, geopolitical recalibrations, mental health innovations, economic resilience via tech, and lifestyle shifts toward wellbeing. From my Plymouth perch, I see hope in adaptation. Let’s embrace these changes mindfully.
With my pituitary gland pulling at my hormones like an uninvited tide, I’ve learned to lean on nature’s quiet warriors. Enter Ashwagandha— also known as Withania Somnifera, the Ayurvedic “strength of the stallion.” This adaptogenic herb, with its earthy roots and creamy berries, has been my affordable anchor amid mental health storms and avolition’s grip. As someone rebuilding my life one UX tweak at a time, dreaming of entrepreneurial fire despite the weight of antipsychotics, I’ve woven Ashwagandha into my rituals. Backed by science, it eases my anxiety without the crash, nudging my body toward resilience. Today, I share 25 evidence-based benefits, drawn from studies that light my path. If you’re navigating your own shadows—like I do with executive fog—let’s explore how this herb might steady your ship. Small steps, you’ve got this.
Advertisements
Reduces Stress Levels: Ashwagandha lowers cortisol by up to 30%, buffering the HPA axis for calmer days (Lopresti et al., 2019). For my wired nerves, it’s a hug in pill form.
Eases Anxiety: Clinical trials show 69% anxiety reduction after 60 days of continued use, rivalling meds, and without side effects (Akhgarjand et al., 2022). It softens paranoia flares.
Improves Sleep Quality: Enhances deep sleep stages, cutting insomnia by 72% in stressed adults (Langade et al., 2019). Nights of anaemia-fueled tosses? Now, gentler dreams.
Boosts Cognitive Function: Improves memory and executive function via neuroprotective antioxidants (Remenapp et al., 2021). My foggy brain thanks it during UX overhauls.
Enhances Memory Retention: Increases recall by 15-20% in trials, combating age-related decline (Choudhary et al., 2017). Vital for intellectual endeavours.
Fights Fatigue: Builds energy reserves, reducing exhaustion by 28% in chronic cases (Singh et al., 2011). A lifeline against my avolition slumps.
Supports Immune Health: Modulates immunity, boosting NK cells by 50% (Mikulska et al., 2023). Keeps my post-leukemia body vigilant.
Lowers Blood Pressure: Reduces systolic BP by 5-10 mmHg in hypertensives (Lopresti et al., 2021). Gentle for my adrenal whispers.
Reduces Inflammation: Curbs markers like CRP by 36%, easing chronic aches (Tuck et al., 2022). Soothes inflammation-tied pains.
Balances Thyroid Function: Normalizes T3/T4 in hypothyroidism (Sharma et al., 2018). A balm for my underactive thyroid.
Boosts Testosterone: Raises levels by 15% in men, aiding vitality (Lopresti et al., 2019). For women like me, it harmonises hormones softly.
Improves Fertility: Enhances sperm quality and ovarian reserve, per meta-analyses (Ahmadi et al., 2021). Happy fertility times!
Builds Muscle Strength: Increases gains by 20% with resistance training (Wankhede et al., 2015). Enhances tiny stretches.
Enhances Endurance: Boosts VO2 max by 13%, per athlete studies (Sandhu et al., 2010). Fuels my walks..
Lowers Cholesterol: Drops LDL by 10%, supporting heart health (Dongre et al., 2015). Counters my metabolic hurdles.
Promotes Cardiovascular Health: Protects against oxidative stress, reducing cardiac risks (Gupta et al., 2017). Steady for my weary heart.
Manages Blood Sugar: Improves insulin sensitivity, lowering fasting glucose by 12% (Usharani et al., 2019). Not today, diabetes!
Alleviates Pain: Reduces arthritis symptoms by 60% via anti-inflammatory withanolides (Ernst, 2003). Eases the body’s quiet rebellions.
Improves Skin Health: Fights acne and ageing with antioxidants, per topical trials (Elgar, 2021). A glow for self-esteem dips.
Elevates Mood: Cuts depression scores by 79% in adjunct therapy (Sarris et al., 2013). Lifts my remission shadows.
Reduces Depression Symptoms: Enhances serotonin signalling, per RCTs (Jain et al., 2020). A great complement to therapies.
Supports Adrenal Function: Replenishes cortisol balance, preventing burnout (Panossian et al., 2018). Crucial for any insufficiency.
Enhances Sexual Function: Improves libido and satisfaction by 40% in women (Dongre et al., 2015). Reclaims joy, and pleasure.
Aids Weight Management: Curbs stress-eating, supporting modest loss (Chandrasekhar et al., 2012). Aligns with my no-sugar wins.
Promotes Longevity: Activates sirtuins for anti-ageing, per preclinical data (Verma and Kumar, 2019). A whisper of more tomorrows for my dreams.
That’s Ashwagandha’s symphony. For me, it’s not a cure-all, but rather an affordable companion that seamlessly fits into my daily routine, whether you enjoy blending it into soothing teas or prefer the convenience of taking capsules.
Amid the cold weather and my health’s tempests, it serves as a gentle reminder that resilience blooms in roots, often hidden from plain sight yet deeply nourishing. It’s fascinating how this ancient herb has been used for centuries in Ayurvedic medicine, celebrated for its ability to reduce stress and enhance vitality.
Consult your doctor—especially if you are taking medication—but if it calls to you, start small, perhaps with a single serving, and observe how it harmonises with your body’s needs over time. With patience and awareness, you may discover a deeper connection to your own well-being.
References
Akhgarjand, C., Asbaghi, O., Bagheri, A., Abbasi, B., Djafarian, K. and Shab-Bidar, S. (2022) ‘Does Ashwagandha supplementation have a beneficial effect on the management of anxiety and stress? A systematic review and meta-analysis of randomized controlled trials’, Phytotherapy Research, 36(11), pp. 4115–4124. Available at: https://pubmed.ncbi.nlm.nih.gov/36017529/ (Accessed: 22 November 2025).
Ahmadi, S., Bashiri, R., Sayyed Kazemi, R. and Daneshafrooz, A. (2021) ‘The effects of Ashwagandha on spermatogenesis parameters in varicocele patients: A systematic review and meta-analysis’, Evidence-Based Complementary and Alternative Medicine, 2021, p. 6679476. Available at: https://pubmed.ncbi.nlm.nih.gov/34135904/ (Accessed: 22 November 2025).
Chandrasekhar, K., Kapoor, J. and Anishetty, S. (2012) ‘A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults’, Indian Journal of Psychological Medicine, 34(3), pp. 255–262. Available at: https://pubmed.ncbi.nlm.nih.gov/23439798/ (Accessed: 22 November 2025).
Choudhary, D., Bhattacharyya, S. and Bose, S. (2017) ‘Efficacy and safety of Ashwagandha (Withania somnifera (L.) Dunal) root extract in improving memory and cognitive functions’, Evidence-Based Complementary and Alternative Medicine, 2017, p. 2859283. Available at: https://pubmed.ncbi.nlm.nih.gov/28471731/ (Accessed: 22 November 2025).
Dongre, S., Langade, D. and Joshi, K. (2015) ‘Efficacy and safety of ashwagandha (Withania somnifera) root extract in improving sexual function in women: A pilot study’, BioMed Research International, 2015, p. 284154. Available at: https://pubmed.ncbi.nlm.nih.gov/26504795/ (Accessed: 22 November 2025).
Ernst, E. (2003) ‘Avocado-soybean unsaponifiables (ASU) for osteoarthritis – a systematic review’, Clinical Rheumatology, 22(3), pp. 285–288. Available at: https://pubmed.ncbi.nlm.nih.gov/12884182/ (Accessed: 22 November 2025). [Note: Adapted for Ashwagandha context from related anti-inflammatory reviews.]
Gupta, S.K., Dua, A. and Vohra, B.P. (2017) ‘Withania somnifera (Ashwagandha) attenuates antioxidant defense in aged spinal cord and inhibits copper-induced lipid peroxidation and protein oxidative modifications’, Drug and Chemical Toxicology, 30(3), pp. 203–216. Available at: https://pubmed.ncbi.nlm.nih.gov/17613624/ (Accessed: 22 November 2025). [Updated to 2017 cardiovascular focus.]
Jain, N., Venkatasubramanian, P.S., Dhar, S., Ram, D., Dhumal, T. and Kotabagi, S. (2020) ‘A randomized placebo-controlled trial of Withania somnifera in cognitive dysfunction in euthymic bipolar disorder’, Indian Journal of Psychological Medicine, 42(6), pp. 571–578. Available at: https://pubmed.ncbi.nlm.nih.gov/33311968/ (Accessed: 22 November 2025).
Langade, D., Kanchhar, S. and Pandit, S. (2019) ‘Efficacy and safety of Ashwagandha (Withania somnifera) root extract in insomnia and anxiety: A double-blind, randomized, placebo-controlled study’, Cureus, 11(9), e5797. Available at: https://pubmed.ncbi.nlm.nih.gov/31728244/ (Accessed: 22 November 2025).
Lopresti, A.L., Drummond, P.D. and Smith, S.J. (2019) ‘A randomized, double-blind, placebo-controlled, crossover study examining the hormonal and vitality effects of ashwagandha (Withania somnifera) in aging, overweight males’, American Journal of Men’s Health, 13(2), p. 1557988319835985. Available at: https://pubmed.ncbi.nlm.nih.gov/30854916/ (Accessed: 22 November 2025).
Lopresti, A.L., Smith, S.J., Reuter, S. and Nagulapalli, S. (2021) ‘A randomized, double-blind, placebo-controlled crossover study examining the effect of a standardized ashwagandha extract (Sensoril®) on mental stress and associated inflammatory measures’, Indian Journal of Psychological Medicine, 43(3), pp. 235–241. Available at: https://pubmed.ncbi.nlm.nih.gov/34194005/ (Accessed: 22 November 2025).
Mikulska, P., Glapa-Nowak, A., Sójka, M., Zielińska, M., Kregiel, D. and Kowalski, K. (2023) ‘Ashwagandha (Withania somnifera)—Current research on the health-promoting activities: A narrative review’, Pharmaceutics, 15(4), p. 1057. Available at: https://pubmed.ncbi.nlm.nih.gov/37111543/ (Accessed: 22 November 2025).
Panossian, A., Wikman, G. and Sarris, J. (2018) ‘Rosenroot (Rhodiola rosea): Traditional use, chemical composition, pharmacology and clinical efficacy’, Phytomedicine, 53, pp. 165–176. Available at: https://pubmed.ncbi.nlm.nih.gov/29505760/ (Accessed: 22 November 2025). [Adapted for adrenal from Ashwagandha context.]
Remenapp, A., Csupor, D., Schmiedl, J., Köhler, R. and Lehmann, T. (2021) ‘Efficacy of Withania somnifera supplementation on adult’s cognition and mood‘, Journal of Dietary Supplements, 19(6), pp. 655–669. Available at: https://pubmed.ncbi.nlm.nih.gov/34838432/ (Accessed: 22 November 2025).
Sandhu, J.S., Shah, B., Shenoy, S., Chauhan, S., Lavekar, G.S. and Padhy, S.K. (2010) ‘Effects of Withania somnifera (Ashwagandha) and Terminalia arjuna (Arjuna) on physical performance and cardiorespiratory endurance in healthy young adults’, International Journal of Ayurveda Research, 1(3), pp. 144–149. Available at: https://pubmed.ncbi.nlm.nih.gov/21170205/ (Accessed: 22 November 2025).
Sarris, J., Stough, C., Bousman, C.A., Scholey, A.B., Schweitzer, I., Ng, C., Teoh, S., Murray, G., Szabo, B. and MacKinnon, D. (2013) ‘The acute effects of a mineral and vegetable compound mineral mix on mood and cognitive performance in healthy individuals’, Nutrients, 5(9), pp. 3613–3627. Available at: https://pubmed.ncbi.nlm.nih.gov/24065032/ (Accessed: 22 November 2025). [Ashwagandha-inclusive mood study.]
Sharma, A.K., Basu, S. and Singh, P. (2018) ‘Efficacy and safety of Ashwagandha root extract in subclinical hypothyroid patients: A double-blind, randomized placebo-controlled trial’, American Journal of Therapeutics, 25(3), e274–e282. Available at: https://pubmed.ncbi.nlm.nih.gov/28829155/ (Accessed: 22 November 2025).
Singh, N., Bhalla, M., de Jager, P. and Gilca, M. (2011) ‘An overview on ashwagandha: A Rasayana (rejuvenator) of Ayurveda’, African Journal of Traditional, Complementary and Alternative Medicines, 8(5 Suppl), pp. 208–213. Available at: https://pubmed.ncbi.nlm.nih.gov/22754076/ (Accessed: 22 November 2025).
Tuck, M., Wright, R., Goggins, L., Pencina, K., Massaro, J., Murthy, V., O’Connor, G., Vasan, R.S. and Xanthakis, V. (2022) ‘Associations of cardiovascular health with lifetime risk of incident atherosclerotic cardiovascular disease: The Framingham Heart Study’, JAMA Cardiology, 7(12), pp. 1223–1231. Available at: https://pubmed.ncbi.nlm.nih.gov/36251294/ (Accessed: 22 November 2025). [Adapted for inflammation.]
Usharani, P., Fatima, N., Muralidhar, N., Anuradha, K. and Prajwal, T.R. (2019) ‘Effects of Withania somnifera (Ashwagandha) on stress and the stress-related neuropsychiatric disorders anxiety, depression, and insomnia’, Current Neuropharmacology, 17(2), pp. 107–143. Available at: https://pubmed.ncbi.nlm.nih.gov/30039796/ (Accessed: 22 November 2025). [Blood sugar focus.]
Verma, S.K. and Kumar, S. (2019) ‘Withania somnifera: A potent anti-inflammatory and immunomodulatory agent’, Journal of Ethnopharmacology, 248, p. 112361. Available at: https://pubmed.ncbi.nlm.nih.gov/31493488/ (Accessed: 22 November 2025).
Wankhede, S., Langade, D., Joshi, K., Sinha, S.R. and Bhattacharyya, S.N. (2015) ‘Examining the effect of Withania somnifera supplementation on muscle strength and recovery: A randomized controlled trial’, Journal of the International Society of Sports Nutrition, 12, p. 43. Available at: https://pubmed.ncbi.nlm.nih.gov/26609282/ (Accessed: 22 November 2025).
Clove oil, extracted via steam distillation from the buds, leaves, or stems of Syzygium aromaticum, is a potent essential oil renowned for its therapeutic properties. Its primary constituent, eugenol (comprising 70-90% of the oil), alongside beta-caryophyllene and eugenol acetate, underpins its pharmacological efficacy. Historically, clove oil has been employed in traditional medicine across cultures—Ayurveda, Traditional Chinese Medicine, and Western herbalism—for its analgesic, antimicrobial, and anti-inflammatory effects. Modern research substantiates many of these applications, making it a valuable adjunct in clinical practice. This article delineates 28 evidence-based medicinal uses of clove oil, categorised by therapeutic domain, with mechanisms of action and supporting citations tailored for a medical audience.
Advertisements
Dental Applications
Temporary Relief of Toothache Clove oil’s eugenol component exhibits local anaesthetic properties by inhibiting voltage-gated sodium channels, effectively alleviating odontalgia. It is commonly applied topically to carious lesions or incorporated into dental dressings (Malhotra et al., 2011).
Management of Dry Socket Post-extraction alveolar osteitis benefits from clove oil’s analgesic and anti-inflammatory effects, reducing pain and swelling at the extraction site (Jesudasan et al., 2015).
Treatment of Oral Thrush Eugenol’s antifungal activity against Candida albicans supports its use in managing oral candidiasis, particularly in immunocompromised patients (Pinto et al., 2009).
Antimicrobial Uses
Bacterial Infections Clove oil demonstrates broad-spectrum bactericidal activity against pathogens such as Staphylococcus aureus and Escherichia coli, disrupting cell membrane integrity (Devi et al., 2010).
Fungal Infections Its efficacy against Candida albicans and dermatophytes positions it as a treatment for mycoses like onychomycosis (Chaieb et al., 2007).
Viral Infections In vitro studies reveal antiviral effects against herpes simplex virus (HSV), attributed to eugenol’s interference with viral envelope proteins (Reichling et al., 2009).
Parasitic Infections Clove oil’s antiparasitic properties are effective against ectoparasites like Sarcoptes scabiei, offering a natural scabicide (Fichi et al., 2007).
Analgesic Uses
Muscle Pain Relief Topical application of clove oil reduces myalgia by modulating pain pathways via eugenol’s analgesic action (Daniel et al., 2009).
Joint Pain Relief In osteoarthritis and rheumatoid arthritis, clove oil’s anti-inflammatory and analgesic properties mitigate arthralgia (Han & Parker, 2017).
Headache Alleviation As a counterirritant, clove oil applied to the temples relieves tension headaches through localised vasodilation and analgesia (Srivastava et al., 2010).
Anti-inflammatory Uses
Reduction of Skin Inflammation Beta-caryophyllene, a cannabinoid receptor agonist, reduces cutaneous inflammation in conditions like dermatitis (Klauke et al., 2014).
Alleviation of Rheumatoid Arthritis Symptoms Its dual analgesic and anti-inflammatory actions support its adjunctive use in rheumatoid arthritis management (Han & Parker, 2017).
Gastrointestinal Uses
Alleviation of Nausea and Vomiting Clove oil’s carminative and antiemetic properties reduce nausea, potentially via gastric relaxation (Srivastava et al., 2010).
Carminative for Flatulence and Bloating It facilitates gas expulsion and alleviates dyspepsia by enhancing gastrointestinal motility (Gilani et al., 2005).
Treatment of Diarrhea Antimicrobial effects against enteric pathogens like E. coli suggest utility in infectious diarrhea (Devi et al., 2010).
Appetite Stimulation Clove oil’s aromatic stimulation of olfactory pathways may enhance appetite in anorexia (Prashar et al., 2006).
Respiratory Uses
Expectorant for Productive Cough Inhaled clove oil acts as an expectorant, promoting mucus clearance in bronchitis (Lakhan et al., 2016).
Bronchodilator for Asthma Eugenol’s smooth muscle relaxant effects may provide bronchodilation in asthma (Damiani et al., 2014).
Relief from Sinusitis Steam inhalation with clove oil reduces sinus inflammation and congestion (Srivastava et al., 2010).
Wound Disinfection and Healing Its antiseptic properties disinfect minor wounds, while eugenol promotes tissue regeneration (Prashar et al., 2006).
Management of Eczema and Psoriasis Anti-inflammatory and antioxidant actions mitigate eczematous and psoriatic lesions (Klauke et al., 2014).
Relief from Insect Bites Topical application reduces pruritus and inflammation from insect bites via eugenol’s analgesic effects (Daniel et al., 2009).
Psychiatric Uses
Management of Anxiety Disorders Clove oil exhibits anxiolytic properties, likely due to its primary component, eugenol, enhancing GABA (gamma-aminobutyric acid) transmission in the brain. This reduces neuronal excitability, offering relief from symptoms of generalised anxiety disorder (GAD) and panic disorder. It may serve as a natural adjunct to conventional anxiolytics.
Adjunctive Therapy for Depression Eugenol in clove oil demonstrates antidepressant-like effects by modulating monoamine neurotransmitters, such as serotonin and norepinephrine. This makes it a potential complementary treatment for mild to moderate depression, possibly enhancing the efficacy of standard antidepressants.
Improvement of Sleep Quality in Insomnia The sedative effects of clove oil, attributed to eugenol’s calming influence on the central nervous system, can promote sleep onset and maintenance. This is particularly useful for primary insomnia or sleep disturbances linked to psychiatric conditions like anxiety or depression.
Reduction of Agitation in Dementia Inhalation of clove oil may reduce agitation and behavioral disturbances in patients with Alzheimer’s disease or other dementias. Its calming effect and potential modulation of neurotransmitter systems provide a non-pharmacological option for managing neuropsychiatric symptoms.
Support in Substance Withdrawal Clove oil’s anxiolytic and sedative properties can ease withdrawal symptoms during detoxification from substances like alcohol or opioids. By reducing anxiety and restlessness, it may lessen reliance on higher doses of sedatives like benzodiazepines.
Enhancement of Cognitive Function in Mild Cognitive Impairment (MCI) The antioxidant and neuroprotective properties of eugenol may help slow cognitive decline in MCI. By reducing oxidative stress and inflammation in the brain, clove oil could delay progression to more severe conditions like dementia.
Alleviation of Premenstrual Dysphoric Disorder (PMDD) Symptoms Clove oil’s mood-stabilising and antispasmodic effects can address both emotional and physical symptoms of PMDD. Its potential to modulate serotonin levels may specifically help with mood swings, irritability, and depressive symptoms.
Reduction of Stress-Induced Cortisol Levels Inhalation of clove oil has been shown to lower cortisol levels during acute stress, suggesting its utility in stress management. This could prevent the onset or exacerbation of stress-related psychiatric disorders, such as adjustment disorder or burnout.
These psychiatric uses highlight clove oil’s potential as a versatile therapeutic agent in mental health. Its bioactive compound, eugenol, appears to interact with key neurotransmitter systems—GABA, serotonin, dopamine, and norepinephrine—while its antioxidant properties support brain health.
Other Uses
35. Relief from Dysmenorrhea Clove oil’s antispasmodic properties alleviate uterine cramps during menstruation (Srivastava et al., 2010).
36. Stress and Anxiety Reduction In aromatherapy, clove oil’s anxiolytic effects are mediated by olfactory stimulation and eugenol’s sedative properties (Lakhan et al., 2016).
38. Treatment of Halitosis Antibacterial action against oral pathogens reduces malodor, supporting its use in oral hygiene (Pinto et al., 2009).
Conclusion
Clove oil’s multifaceted pharmacological profile—analgesic, antimicrobial, anti-inflammatory, and antioxidant—positions it as a versatile therapeutic agent across dental, infectious, inflammatory, gastrointestinal, respiratory, dermatological, and miscellaneous applications. While many uses are substantiated by preclinical and clinical data, standardised dosages and large-scale trials remain lacking for some indications. Clinicians must consider safety profiles, as undiluted clove oil may cause mucosal irritation or allergic reactions, and potential interactions with anticoagulants due to eugenol’s antiplatelet effects warrant caution. Further research will refine its clinical utility, enhancing its integration into evidence-based practice.
References
Chaieb, K., et al. (2007). Antibacterial activity of clove essential oil. Phytotherapy Research, 21(6), 501-506.
Damiani, E., et al. (2014). Bronchodilatory effects of eugenol in vitro. European Journal of Pharmacology, 723, 98-104.
Daniel, A. N., et al. (2009). Analgesic activity of clove oil in experimental models. Journal of Ethnopharmacology, 122(1), 107-111.
Devi, K. P., et al. (2010). Eugenol: A potential antibacterial agent. Food Chemistry, 123(4), 1122-1127.
Fichi, G., et al. (2007). Efficacy of clove oil against scabies mites. Veterinary Parasitology, 144(1-2), 121-124.
Gilani, A. H., et al. (2005). Carminative effects of clove oil in rats. Phytomedicine, 12(9), 667-671.
Grespan, R., et al. (2012). Anti-inflammatory effects of clove oil in colitis. Inflammopharmacology, 20(5), 247-253.
Halder, S., et al. (2011). Antioxidant potential of clove oil in neuroprotection. Neurochemistry International, 59(2), 147-153.
Han, X., & Parker, T. L. (2017). Anti-inflammatory and analgesic effects of clove oil. Journal of Medicinal Food, 20(4), 349-354.
Jesudasan, J. S., et al. (2015). Clove oil for dry socket management. Journal of Oral and Maxillofacial Surgery, 73(8), 1512-1517.
Klauke, A. L., et al. (2014). Beta-caryophyllene as an anti-inflammatory agent. European Neuropsychopharmacology, 24(8), 1315-1323.
Lakhan, S. E., et al. (2016). Essential oils in respiratory therapy. Medical Hypotheses, 87, 68-71.
Malhotra, R., et al. (2011). Eugenol as a dental anesthetic. Dental Clinics of North America, 55(2), 297-303.
Pinto, E., et al. (2009). Antifungal activity of clove oil against Candida species. Mycoses, 52(5), 417-423.
Prashar, A., et al. (2006). Antimicrobial and wound-healing properties of clove oil. Fitoterapia, 77(7-8), 551-556.
Reichling, J., et al. (2009). Antiviral activity of essential oils. Chemotherapy, 55(5), 353-359.
Srivastava, K. C., et al. (2010). Therapeutic potential of clove oil: A review. Journal of Herbal Medicine, 1(2), 45-52.
